Back
Aclaris Therapeutics Quote, Financials, Valuation and Earnings
The Mysterious VC Firm Behind Nvidia's Secret Weapon
Details Here!
Buy
73
ACRS
Aclaris Therapeutics
Last Price:
2.56
Seasonality Move:
32.55%
7 Day Trial
ALL ACCESS PASS
$
7
"This Changes Everything" - Trump Hands Millions Massive IRS Gift
Learn More HereAclaris Therapeutics Price Quote
$2.56
-0.07 (-2.66%)
(Updated: November 12, 2024 at 5:55 PM ET)
Aclaris Therapeutics Key Stats
Buy
73
Aclaris Therapeutics (ACRS)
is a Buy
Day range:
$2.09 - $2.68
52-week range:
$0.59 - $2.68
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
6.91
P/B ratio:
1.44%
Volume:
1.8M
Avg. volume:
813.9K
1-year change:
-44.69%
Market cap:
$187.6M
Revenue:
$31.2M
EPS:
$-0.52
How Much Does Aclaris Therapeutics Make?
-
How Much Are Aclaris Therapeutics's Sales Annually?
ACRS Revenues are $31.2M -
How Much Profit Does Aclaris Therapeutics's Make A Year?
ACRS net income is -$88.5M
Is Aclaris Therapeutics Growing As A Company?
-
What Is Aclaris Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.53% -
What Is Aclaris Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Aclaris Therapeutics Stock Price Performance
-
Did Aclaris Therapeutics Stock Go Up Last Month?
Aclaris Therapeutics share price went up by 122.88% last month -
Did ACRS's Share Price Rise Over The Last Year?
ACRS share price fell by -44.69% over the past 1 year
What Is Aclaris Therapeutics 52-Week High & Low?
-
What Is Aclaris Therapeutics’s 52-Week High Share Price?
Aclaris Therapeutics has traded as high as $2.68 over the past 52 weeks -
What Is Aclaris Therapeutics’s 52-Week Low Share Price?
Aclaris Therapeutics has traded as low as $0.59 over the past 52 weeks
Aclaris Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Aclaris Therapeutics?
-
How Much Debt Does Aclaris Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Aclaris Therapeutics Have?
Cash and short term investments quarterly total is $173.4M -
What Is Aclaris Therapeutics’s Book Value Per Share?
Book value per share is 1.82
Is Aclaris Therapeutics Cash Flow Positive?
-
What Is ACRS Cash Flow From Operations?
Cash flow from operations (TTM) is -$17.9M -
What Is Aclaris Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $49K -
What Is Aclaris Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $7.6M
Aclaris Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
ACRS return on invested capital is -25.72% -
What Is Aclaris Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -19.83% -
What Is ACRS Return On Equity?
ROE is a measure of profitability and is -25.72%
Aclaris Therapeutics Earnings Date & Stock Price
-
What Is Aclaris Therapeutics's Stock Price Today?
A single share of ACRS can be purchased today for 2.63 -
What Is Aclaris Therapeutics’s Stock Symbol?
Aclaris Therapeutics trades on the nasdaq under the ticker symbol: ACRS -
When Is Aclaris Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Aclaris Therapeutics is scheduled on February 27, 2025 -
When Is ACRS's next ex-dividend date?
Aclaris Therapeutics's next ex-dividend date is November 13, 2024 -
How To Buy Aclaris Therapeutics Stock?
You can buy Aclaris Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Aclaris Therapeutics Competitors
-
Who Are Aclaris Therapeutics's Competitors?
Below is a list of companies who compete with Aclaris Therapeutics or are related in some way:
Aclaris Therapeutics Dividend Yield
-
What Is ACRS Dividend Yield?
Aclaris Therapeutics’s dividend yield currently is 0% -
What Is Aclaris Therapeutics’s Payout Ratio?
Aclaris Therapeutics’s payout ratio is 0% -
When Did Aclaris Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 13, 2024 -
What Is Aclaris Therapeutics’s Dividend Per Share?
Aclaris Therapeutics pays a dividend of $0.00 per share
Aclaris Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -1275% |
| Revenue: | -53.18% | -63.32% |
Analyst Recommendations
| Buy Recommendations: | 0 |
|---|---|
| Hold Recommendations: | 7 |
| Sell Recommendations: | 0 |
| Price Target: | 2.30 |
| Downside from Last Price: | -12.55% |